Related Experiment Video
Updated: Mar 2, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Cardioversion in Acute Atrial Fibrillation Without Anticoagulation
Ke Juhani Airaksinen1, Wail Nammas1, Ilpo Nuotio1
1Heart Center,Turku University Hospital and University of Turku,Turku,Finland.
Insights
Cardioversion for atrial fibrillation carries a risk of thromboembolism, especially in patients with stroke risk factors. However, evidence suggests low risk without anticoagulation in those without risk factors.
Area of Science:
- Cardiology
- Electrophysiology
- Thrombosis
Background:
- Cardioversion of acute atrial fibrillation poses a risk of thromboembolic events, primarily within the first week post-procedure.
- Transesophageal echocardiography reveals potential thrombus formation and spontaneous echo contrast in the left atrium and appendage.
- Atrial function may be impaired immediately after successful cardioversion, increasing event risk.
Purpose of the Study:
- To evaluate the thromboembolic risk associated with cardioversion of acute atrial fibrillation.
- To assess the impact of stroke risk factors on post-cardioversion thromboembolic events.
- To inform anticoagulation strategies following cardioversion.
Main Methods:
- Review of a large patient population undergoing cardioversion for acute atrial fibrillation.
- Analysis of thromboembolic event rates based on the presence or absence of classic stroke risk factors.
- Comparison of outcomes with and without anticoagulation therapy.
Main Results:
- Patients without stroke risk factors exhibited a low overall risk of thromboembolic events after cardioversion without anticoagulation.
- Patients with multiple classic stroke risk factors faced a significantly higher risk, around 10%.
- Current guidelines recommend anticoagulation for moderate-to-high risk patients.
Conclusions:
- Successful cardioversion of acute atrial fibrillation in low-risk patients may not require anticoagulation.
- Patients with multiple stroke risk factors remain at high risk and necessitate anticoagulation.
- Risk stratification is crucial for guiding anticoagulation decisions post-cardioversion.
Abstract:
A major concern in cardioversion of newly detected atrial fibrillation is the risk of thromboembolic events. The vast majority of these events occur in the first week following cardioversion. Transesophageal echocardiography has demonstrated that thrombus and dense spontaneous echo contrast may occur in the left atrium and left atrial appendage in patients with acute atrial fibrillation (<48 hours) scheduled for cardioversion. Moreover, atrial function may become impaired immediately following successful cardioversion. The risk of thromboembolic events increases with the presence of stroke risk factors, such as heart failure, hypertension, diabetes, prior stroke, female sex and age above 65-75 years. Thus, the current guidelines of the ESC and ACC/AHA/Heart Rhythm Society recommend that patients with acute atrial fibrillation should undergo cardioversion under cover of unfractionated or low-molecular weight heparin followed by oral anticoagulation for at least 4 weeks in patients in patients at moderate-to-high risk for stroke. In line with the guidelines, new evidence from a large patient population suggests that after successful cardioversion of acute atrial fibrillation, patients have a low overall risk of thromboembolic events without any anticoagulation when they have no risk factors for thromboembolism. In contrast, the risk is in the range of 10% in patients with multiple classic risk factors for thromboembolism.
Related Concept Videos
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
01:29Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:23Cardiopulmonary Resuscitation III: AED Use
01:25Dysrhythmias VI: Management of Dysrhythmias
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...